Details of the Drug

General Information of Drug (ID: DMDCHM7)

Drug Name
BMS-986016
Indication
Disease Entry ICD 11 Status REF
Hematologic tumour 2B33.Y Phase 1/2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD ID
D03ZSA
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lymphocyte activation gene 3 protein (LAG3) TTNVXAW LAG3_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02061761) Safety Study of Anti-LAG-3 in CLL, HL, NHL and MM. U.S. National Institutes of Health.
2 Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 March; 7(2): 85-96.